Sep 18 |
Plus Therapeutics Showcases New Interim ReSPECT-GBM Phase 2 Trial Data at the 2024 Congress of Neurological Surgeons Annual Meeting
|
Sep 4 |
Plus Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
|
Aug 13 |
Plus Therapeutics Q2 2024 Earnings Preview
|
Aug 13 |
Plus Therapeutics Presents Positive Clinical Trial Results at theĀ 2024 SNO/ASCO CNS Metastases Conference
|
Aug 12 |
Plus Therapeutics Presents Positive Interim ReSPECT-LM Phase 1 Data for Leptomeningeal Metastases at 2024 SNO/ASCO CNS Metastases Conference
|
Aug 8 |
Plus Therapeutics to Announce Second Quarter Financial Results and Host Conference Call on August 14, 2024
|
Jul 2 |
Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
|
Jun 7 |
Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
|
May 17 |
Plus Therapeutics Announces New Employment Inducement Grants
|
May 16 |
Plus Therapeutics Inc (PSTV) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress ...
|